The last time I spoke about AtaiBeckley (ATAI), it was with a Seeking Alpha article entitled "Atai: Inidascamine Trial Failure Doesn't Matter In Main Psychedelic Pipeline Focus." With respect to this ...
BPL‑003 holds Breakthrough Therapy Designation and is supported by positive Phase 2b results in treatment-resistant depression Cash runway reaffirmed through the planned early-2029 topline readouts ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results